The present invention is directed to oral, therapeutically effective pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof, including delayed onset and controlled release dosage forms. The present invention is also directed delayed onset, rapid release dosage forms and delayed onset, extended release dosage forms of oral buprenorphine which provide robust efficacy and reduced potential for abuse and misuse.
